Skip to content

Quadro-Iliac Plane Block for Analgesia After Lumbar Microdiscectomy

Effect of Ultrasound-Guided Quadro-Iliac Plane Block Compared With Local Infiltration Analgesia After Single-Level Lumbar Microdiscectomy: A Prospective, Double-Blind, Controlled, Multicenter Randomized Trial

Status
Not yet recruiting
Phases
Unknown
Study type
Interventional
Source
ClinicalTrials.gov
Registry ID
NCT07695987
Acronym
QIPB RCT
Enrollment
60
Registered
2026-07-10
Start date
2026-07-10
Completion date
2026-12-02
Last updated
2026-07-10

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Pain Management

Brief summary

This study will evaluate whether ultrasound-guided quadro-iliac plane block provides better postoperative pain control than local infiltration analgesia in patients undergoing single-level lumbar microdiscectomy. Adult patients scheduled for elective single-level lumbar microdiscectomy will be randomly assigned to receive either bilateral quadro-iliac plane block plus patient-controlled analgesia or local infiltration analgesia plus patient-controlled analgesia. The main outcome of the study will be total fentanyl consumption during the first 24 hours after surgery. Pain scores, need for rescue analgesia, opioid-related side effects, patient satisfaction, and recovery quality will also be evaluated.

Detailed description

This is a prospective, randomized, double-blind, controlled, multicenter clinical trial designed to assess the analgesic efficacy of ultrasound-guided quadro-iliac plane block in patients undergoing elective single-level lumbar microdiscectomy. Patients aged 18-75 years with American Society of Anesthesiologists physical status I-III who are scheduled for elective single-level lumbar microdiscectomy under general anesthesia will be included. Participants will be randomized into two groups. The intervention group will receive bilateral ultrasound-guided quadro-iliac plane block before emergence from anesthesia, followed by postoperative patient-controlled analgesia. The control group will receive local infiltration analgesia performed by the surgeon, followed by postoperative patient-controlled analgesia. All patients will receive a standardized general anesthesia protocol. Postoperative analgesia will be provided using a fentanyl-based patient-controlled analgesia device. The primary outcome will be total fentanyl consumption during the first postoperative 24 hours. Secondary outcomes will include numerical rating scale pain scores at predefined postoperative time points, rescue analgesic requirement, opioid-related adverse effects such as nausea, vomiting, pruritus and respiratory depression, dermatomal sensory spread, and patient-reported recovery quality using the QoR-15 questionnaire.

Interventions

PROCEDUREUltrasound-Guided Quadro-Iliac Plane Block

Bilateral ultrasound-guided quadro-iliac plane block will be performed before emergence from general anesthesia in the prone position. After visualization of the quadratus lumborum muscle and iliac crest at the L3 level, 30 mL of 0.167% bupivacaine will be injected into the interfascial plane on each side. All participants will receive postoperative fentanyl-based patient-controlled analgesia.

Local infiltration analgesia will be performed by the surgeon before the end of surgery. A total dose of 50 mg of 0.25% bupivacaine will be infiltrated into the subcutaneous tissue. All participants will receive postoperative fentanyl-based patient-controlled analgesia.

Sponsors

Kanuni Sultan Suleyman Training and Research Hospital
Lead SponsorOTHER

Study design

Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
TREATMENT
Masking
DOUBLE (Subject, Outcomes Assessor)

Masking description

Participants and the postoperative outcomes assessor will be blinded to group allocation. The anesthesiologist performing the block procedure will not take part in postoperative data collection or outcome assessment.

Eligibility

Sex/Gender
ALL
Age
18 Years to 75 Years
Healthy volunteers
No

Inclusion criteria

* Adults aged 18 to 75 years * American Society of Anesthesiologists physical status I to III * Scheduled for elective single-level lumbar microdiscectomy, such as L4-L5 or L5-S1 disc herniation * Planned surgery under general anesthesia * Able to provide written informed consent

Exclusion criteria

* Allergy or hypersensitivity to local anesthetics * Coagulopathy or active anticoagulant use * Infection, scar tissue, or skin lesion at the injection site * Pregnancy or breastfeeding * Chronic pain syndrome or regular opioid use * American Society of Anesthesiologists physical status IV or higher * Planned surgery for two or more levels of disc herniation

Design outcomes

Primary

MeasureTime frameDescription
Total Fentanyl Consumption During the First 24 Hours After SurgeryPostoperative 0-24 hoursTotal postoperative fentanyl consumption administered via patient-controlled analgesia will be recorded during the first 24 hours after surgery.

Secondary

MeasureTime frameDescription
Postoperative Pain Scores at Rest and During MovementPostoperative 0, 1, 6, 12, and 24 hoursPain intensity will be assessed using the Numerical Rating Scale at rest and during movement. The scale ranges from 0 to 10, where 0 indicates no pain and 10 indicates the worst imaginable pain.
Rescue Analgesic RequirementPostoperative 0-24 hoursThe need for rescue analgesia with intravenous tenoxicam will be recorded during the postoperative follow-up period.
Opioid-Related Adverse EffectsPostoperative 0-24 hoursOpioid-related adverse effects, including nausea, vomiting, pruritus, and respiratory depression, will be recorded.
Quality of Recovery ScorePostoperative 24 hoursPatient-reported recovery quality will be assessed using the Quality of Recovery-15 questionnaire.
Dermatomal Sensory SpreadPostoperative 2 hoursDermatomal sensory spread of the block will be evaluated using a cold test.

Countries

Turkey (Türkiye)

Contacts

CONTACTEngin ihsan Turan, principal investigator
drenginihsan@gmail.com+905382431114

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Jul 11, 2026